Clinical Trial Update: Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer [Phase 4]

View source ↗

Summary

Phase 4 safety study update on adjuvant docetaxel-carboplatin after resection of non-small cell lung cancer. The study is completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Carboplatin (Paraplatin) (carboplatin)
• Docetaxel (Taxotere) (docetaxel)

Snippet

Sponsor: Michael Mann | Conditions: Non-small Cell Lung Cancer | Phase 4 | Status: COMPLETED | Results posted: 2013-12-18